Literature DB >> 28526762

Exacerbation of Thromboinflammation by Hyperglycemia Precipitates Cerebral Infarct Growth and Hemorrhagic Transformation.

Jean-Philippe Desilles1, Varouna Syvannarath2, Véronique Ollivier2, Clément Journé2, Sandrine Delbosc2, Célina Ducroux2, William Boisseau2, Liliane Louedec2, Lucas Di Meglio2, Stéphane Loyau2, Martine Jandrot-Perrus2, Louis Potier2, Jean-Baptiste Michel2, Mikael Mazighi2, Benoit Ho-Tin-Noé2.   

Abstract

BACKGROUND AND
PURPOSE: Admission hyperglycemia is associated with a poor outcome in acute ischemic stroke. How hyperglycemia impacts the pathophysiology of acute ischemic stroke remains largely unknown. We investigated how preexisting hyperglycemia increases ischemia/reperfusion cerebral injury.
METHODS: Normoglycemic and streptozotocin-treated hyperglycemic rats were subjected to transient middle cerebral artery occlusion. Infarct growth and brain perfusion were assessed by magnetic resonance imaging. Markers of platelet, coagulation, and neutrophil activation were measured in brain homogenates and plasma. Downstream microvascular thromboinflammation (DMT) was investigated by intravital microscopy.
RESULTS: Hyperglycemic rats had an increased infarct volume with an increased blood-brain barrier disruption and hemorrhagic transformation rate compared with normoglycemic rats. Magnetic resonance imaging scans revealed that hyperglycemia enhanced and accelerated lesion growth and was associated with hemorrhagic transformation originating from territories that were still not completely reperfused at 1 hour after middle cerebral artery recanalization. Intravital microscopy and analysis of brain homogenates showed that DMT began immediately after middle cerebral artery occlusion and was exacerbated by hyperglycemia. Measurement of plasma serotonin and matrix metalloproteinase-9 indicated that platelets and neutrophils were preactivated in hyperglycemic rats. Neutrophils from hyperglycemic diabetic patients showed increased adhesion to endothelial cells as compared with neutrophils from normoglycemic donors in flow chamber experiments.
CONCLUSIONS: We show that hyperglycemia primes the thromboinflammatory cascade, thus, amplifying middle cerebral artery occlusion-induced DMT. DMT exacerbation in hyperglycemic rats impaired reperfusion and precipitated neurovascular damage, blood-brain barrier disruption, and hemorrhagic transformation. Our results designate DMT as a possible target for reduction of the deleterious impact of hyperglycemia in acute ischemic stroke.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  acute stroke; hyperglycemia; microvascular dysfunction; middle cerebral artery occlusion; polymorphonuclear neutrophils activation

Mesh:

Year:  2017        PMID: 28526762     DOI: 10.1161/STROKEAHA.117.017080

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  30 in total

1.  Reduced Ischemic Lesion Growth with Heparin in Acute Ischemic Stroke.

Authors:  Eva A Rocha; Ruijun Ji; Hakan Ay; Zixiao Li; Ethem Murat Arsava; Gisele S Silva; Alma Gregory Sorensen; Ona Wu; Aneesh B Singhal
Journal:  J Stroke Cerebrovasc Dis       Date:  2019-03-29       Impact factor: 2.136

2.  MMP10 Promotes Efficient Thrombolysis After Ischemic Stroke in Mice with Induced Diabetes.

Authors:  Manuel Navarro-Oviedo; Carmen Roncal; Agustina Salicio; Miriam Belzunce; Obdulia Rabal; Estefanía Toledo; Beatriz Zandio; Jose A Rodríguez; Jose A Páramo; Roberto Muñoz; Josune Orbe
Journal:  Transl Stroke Res       Date:  2018-07-27       Impact factor: 6.829

Review 3.  Hemorrhagic Transformation After Tissue Plasminogen Activator Treatment in Acute Ischemic Stroke.

Authors:  Chengli Liu; Jie Xie; Shanshan Sun; Hui Li; Tianyu Li; Chao Jiang; Xuemei Chen; Junmin Wang; Anh Le; Jiarui Wang; Zhanfei Li; Jian Wang; Wei Wang
Journal:  Cell Mol Neurobiol       Date:  2020-10-30       Impact factor: 5.046

Review 4.  Preclinical Stroke Research and Translational Failure: A Bird's Eye View on Preventable Variables.

Authors:  Devendra Singh; Himika Wasan; K H Reeta
Journal:  Cell Mol Neurobiol       Date:  2021-03-30       Impact factor: 4.231

5.  Thrombectomy for Comatose Patients with Basilar Artery Occlusion : A Multicenter Study.

Authors:  Adrien Guenego; Ludovic Lucas; Benjamin Gory; Sébastien Richard; Mathilde Aubertin; David Weisenburger-Lile; Julien Labreuche; Cyril Dargazanli; Amel Benali; Romain Bourcier; Lili Detraz; Stéphane Vannier; Maud Guillen; François Eugene; Gregory Walker; Ronda Lun; Andrew Wormsbecker; Célina Ducroux; Michel Piotin; Raphael Blanc; Arturo Consoli; Bertrand Lapergue; Robert Fahed
Journal:  Clin Neuroradiol       Date:  2021-03-11       Impact factor: 3.649

Review 6.  Hemorrhagic Transformation in Ischemic Stroke and the Role of Inflammation.

Authors:  Elena Spronk; Gina Sykes; Sarina Falcione; Danielle Munsterman; Twinkle Joy; Joseph Kamtchum-Tatuene; Glen C Jickling
Journal:  Front Neurol       Date:  2021-05-14       Impact factor: 4.003

7.  Downregulation of CD151 restricts VCAM-1 mediated leukocyte infiltration to reduce neurobiological injuries after experimental stroke.

Authors:  Ceshu Gao; Wangyue Jia; Wendeng Xu; Qiong Wu; Jian Wu
Journal:  J Neuroinflammation       Date:  2021-05-22       Impact factor: 8.322

8.  Verapamil as an Adjunct Therapy to Reduce tPA Toxicity in Hyperglycemic Stroke: Implication of TXNIP/NLRP3 Inflammasome.

Authors:  Saifudeen Ismael; Sanaz Nasoohi; Arum Yoo; Golnoush Mirzahosseini; Heba A Ahmed; Tauheed Ishrat
Journal:  Mol Neurobiol       Date:  2021-04-13       Impact factor: 5.682

9.  Hyperglycemia exacerbates ischemic stroke outcome independent of platelet glucose uptake.

Authors:  Frederik Denorme; Irina Portier; Yasuhiro Kosaka; Robert A Campbell
Journal:  J Thromb Haemost       Date:  2020-11-27       Impact factor: 5.824

10.  Tissue Plasminogen Activator Promotes TXNIP-NLRP3 Inflammasome Activation after Hyperglycemic Stroke in Mice.

Authors:  Saifudeen Ismael; Sanaz Nasoohi; Arum Yoo; Heba A Ahmed; Tauheed Ishrat
Journal:  Mol Neurobiol       Date:  2020-03-14       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.